LifeSci Capital analyst Rami Katkhuda downgraded Tourmaline Bio (TRML) to Market Perform from Outperform with a $48 price target fter Novartis (NVS) announced a deal to acquire Tourmaline for $48.00 per share in cash.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Hold Rating Maintained Amidst Novartis’s Strategic Acquisition of Tourmaline Bio: Balancing Opportunities and Risks
- Tourmaline Bio downgraded to Neutral from Buy at Guggenheim
- Tourmaline Bio downgraded to Neutral from Outperform at Wedbush
- Novartis Seals $1.4B Deal with Tourmaline Bio (TRML) to Bolster Heart Disease Portfolio
- Tourmaline Bio Merges with Novartis for $1.4 Billion